BioSpace News Archive

Genetown

Nightstar Therapeutics to Present at 2018 Chardan Genetic Medicines Conference

Nightstar Therapeutics plc today announced that the company plans on presenting at the Chardan Genetic Medicines Conference, on Tuesday October 9, 2018 at 2:45 p.m. ET in New York City.

October 4, 2018
·
1 min read
Genetown

7 In 10 Massachusetts Residents Believe Narcan Should Be Made Widely Available In Workplaces, According To New Poll Released By Blue Cross Blue Shield Of Massachusetts

State’s largest insurer launches first opioid toolkit for employers to help prevent lethal overdoses

October 4, 2018
·
4 min read
Drug Development

Zealand Pharma enrolls first patient in Phase 3 trial with glepaglutide for the treatment of short bowel syndrome

Zealand Pharma enrolls first patient in Phase 3 trial with glepaglutide for the treatment of short bowel syndrome

October 4, 2018
·
3 min read
Biotech Bay

Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders

Ardelyx, Inc. (Nasdaq: ARDX), today announced that it will hold an investor event called “Renal Day” on Thursday, Oct. 11, 2018, from 8 to 10 a.m. ET in New York City.

October 4, 2018
·
2 min read
Drug Development

Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes

All investigated doses met the primary efficacy endpoint defined as a change from baseline in A1C versus placebo after 26 weeks of treatment

October 4, 2018
·
8 min read
Drug Development

Merck’s HIV Therapy DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens

Merck today announced the first presentation of data from the Phase 3 DRIVE-SHIFT trial evaluating a switch of medication to DELSTRIGO™

October 4, 2018
·
12 min read
Genetown

Zafgen to Present Data from Multiple Nonclinical, IND-Enabling Studies of ZGN-1258 at the 2018 Foundation for Prader-Willi Research Family Conference

Nonclinical data for ZGN-1258 reproduce efficacy seen in first generation candidate for PWS.

October 4, 2018
·
9 min read
Drug Development

ACell Announces New Research Investigating its Hernia Devices in Regenerative Medicine

Pre-Clinical Model Demonstrates Mechanical Strength and Superior Tissue Remodeling Properties of Gentrix® Surgical Matrix Devices.

October 4, 2018
·
2 min read
Drug Development

REGENXBIO Announces Completion of Dosing of Fourth Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD

Clinical trial evaluates one-time treatment for wet AMD using NAV AAV8 gene therapy.

October 4, 2018
·
7 min read
Drug Development

Viking Therapeutics Announces VK2809 Phase 2 Study Results Selected for Oral Late-Breaker Presentation at The Liver Meeting® 2018

Presentation to Highlight Positive 12-Week Data for Novel, Liver-Selective Thyroid Receptor Beta Agonist in Patients with Non-Alcoholic Fatty Liver Disease and Elevated LDL-Cholesterol.

October 4, 2018
·
6 min read